Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Intrinsic Value
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. [ Read More ]
The intrinsic value of one
LALPATHLAB
stock under the Base Case scenario is
1 555.2
INR.
Compared to the current market price of 2 209.2 INR,
Dr. Lal PathLabs Ltd
is
Overvalued by 30%.
LALPATHLAB's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
LALPATHLAB or that its price is influenced by factors unrelated to fundamentals.
Dr. Lal PathLabs Ltd's market capitalization is 183.6B INR.
LALPATHLAB stock price is 2 209.2 INR.
LALPATHLAB stock (1 555.2 INR) is 30% less than its price (2209.2 INR).
LALPATHLAB stock (517.4 INR) is 77% less than its price (2209.2 INR). Open DCF Valuation
LALPATHLAB stock price (2209.2 INR) is 15% less than its Relative Value (2 593 INR). Open Relative Valuation
LALPATHLAB has upside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
LALPATHLAB's Revenue has grown by 8% over the past 12 months.
LALPATHLAB's ROE (Return on Equity) has decreased in the last 3 years from 26% to 20%.
LALPATHLAB has positive Net Income for the last twelve months.
LALPATHLAB's ROE (Return on Equity) for the past 12 months is positive and is equal to 20%.
LALPATHLAB's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
LALPATHLAB's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 22%.
LALPATHLAB has positive Operating Income for the last twelve months.
LALPATHLAB's Revenue has been growing by 14% per year for the last 3 years.
LALPATHLAB's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 55% to 22%.
LALPATHLAB has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
LALPATHLAB has positive Free Cash Flow for the last twelve months.
LALPATHLAB earns more than enough operating income (4B INR) to safely cover interest payments on its debt (341m INR).
LALPATHLAB's short-term assets (11B INR) exceed its short-term liabilties (5B INR).
LALPATHLAB has positive Gross Profit for the last twelve months.
LALPATHLAB has very high three-year average ROIC (Return on Invested Capital): 39%. The company is very efficient at using invested capital to generate operating income.
LALPATHLAB's long-term assets (24B INR) exceed its long-term liabilties (7B INR).
LALPATHLAB's D/E (Debt to Equity) is very low and is equal to 0.09.
LALPATHLAB has negative Net Debt. This means that the company has more cash and short-term investments (9B INR) than debt (2B INR).
LALPATHLAB's Altman Z-Score is very high and is equal to 21.39.
Valuation Backtest
Dr. Lal PathLabs Ltd
Run backtest to discover the historical profit from buying and selling
LALPATHLAB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Dr. Lal PathLabs Ltd
Balance Sheet Decomposition
Dr. Lal PathLabs Ltd
| Current Assets | 10.8B |
| Cash & Short-Term Investments | 9.3B |
| Receivables | 867m |
| Other Current Assets | 626m |
| Non-Current Assets | 13.7B |
| Long-Term Investments | 587m |
| PP&E | 3.6B |
| Intangibles | 8.8B |
| Other Non-Current Assets | 727m |
| Current Liabilities | 4.7B |
| Accounts Payable | 1.9B |
| Other Current Liabilities | 2.8B |
| Non-Current Liabilities | 2B |
| Long-Term Debt | 1.7B |
| Other Non-Current Liabilities | 371m |
Earnings Waterfall
Dr. Lal PathLabs Ltd
|
Revenue
|
21.7B
INR
|
|
Cost of Revenue
|
-4.5B
INR
|
|
Gross Profit
|
17.2B
INR
|
|
Operating Expenses
|
-12.9B
INR
|
|
Operating Income
|
4.4B
INR
|
|
Other Expenses
|
-1.1B
INR
|
|
Net Income
|
3.3B
INR
|
Free Cash Flow Analysis
Dr. Lal PathLabs Ltd
What is Free Cash Flow?
LALPATHLAB Profitability Score
Profitability Due Diligence
Dr. Lal PathLabs Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Dr. Lal PathLabs Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
LALPATHLAB Solvency Score
Solvency Due Diligence
Dr. Lal PathLabs Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Dr. Lal PathLabs Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LALPATHLAB Price Targets Summary
Dr. Lal PathLabs Ltd
According to Wall Street analysts, the average 1-year price target for
LALPATHLAB
is 2 518.1 INR
with a low forecast of 1 686.7 INR and a high forecast of 3 340.05 INR.
Shareholder Return
LALPATHLAB Price
Dr. Lal PathLabs Ltd
| Average Annual Return | 30.67% |
| Standard Deviation of Annual Returns | 49.36% |
| Max Drawdown | -57% |
| Market Capitalization | 183.6B INR |
| Shares Outstanding | 83 299 180 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Dr. Lal PathLabs Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,110 full-time employees. The company went IPO on 2015-12-23. The firm is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The firm offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one
LALPATHLAB
stock under the Base Case scenario is
1 555.2
INR.
Compared to the current market price of 2 209.2 INR,
Dr. Lal PathLabs Ltd
is
Overvalued by 30%.
You don't have any saved screeners yet
